Why read this: This piece offers a compact, contemporary case study in how a single drug class — the GLP-1s now sold as Ozempic, Wegovy and Zepbound — has pushed an entire research field to revisit a foundational question: what actually drives the urge to eat? It is a chance for advanced readers to track a science-journalism argument that interleaves a patient narrative, a 1940s biology backstory, and an explicitly unresolved mechanism. The reframe of obesity from a willpower story to a brain-behaviour story is the kind of move students should learn to detect when reading expert commentary in any discipline.
What to notice: Watch how the article holds three threads simultaneously without explicit signposting: Lena Smith Parker's voices, the set-point model, and the drug-mechanism question. Notice the hedging — 'seems to,' 'may,' 'partly physiological,' 'the unresolved question' — and the way it carries the writer's epistemic stance: researchers think the GLP-1s reset the set point, but the mechanism is not yet characterized. Notice also the figurative reach: 'food noise will kick in,' 'a perfect storm for weight regain,' the food noise that 'returned with a vengeance,' and Leibel's aspirin-fever analogy that quietly reframes the drugs as suppression, not cure.
Skills practised: Synthesising evidence across narrative, history and mechanism; reading hedged claims as deliberate scientific positioning rather than vagueness; identifying the editorial reframe carried by a closing quotation (Drucker on people 'who have never had their brains driving their behavior'); parsing dense compound noun phrases such as scientific advisory boards, weight-loss clinic and clinical trial of tirzepatide as single units; and tracking a multi-character cast (Kaplan, Hirsch, Leibel, Jastreboff, Drucker, Smith Parker, Winfrey) by role rather than name.
"The Day the Food Noise Died"
"GLP-1 drugs have switched off a relentless inner buzz that science barely studied — and the silence is forcing obesity research to rethink what hunger really is."
Tap any green word in the article to see its meaning.
Until the new arrived on the market, the term "food noise" lived nowhere on any . Researchers developing Ozempic, Wegovy, Mounjaro and Zepbound measured doses, , and improvements in diabetes, heart disease and , while the incessant chatter inside patients' heads — what to eat, what to resist, when to give in — went entirely unrecorded. Then patients began reporting that the chatter had simply gone quiet, and an unstudied phenomenon walked into the clinic demanding a name.
Lena Smith Parker, 53, spent decades dieting and regaining weight, plagued by an she had long assumed everyone shared. She likens one voice to a relentless auctioneer urging her toward the cake in the kitchen, another to a used-car salesman shaming her vegetables, a third to a flat-out bully, and a fourth to an advance planner staging cupcake runs days ahead. This is the the article names — a churning internal dialogue no clinician used to ask about, because no drug seemed capable of touching it.
To understand why such voices exist, researchers turn to an elusive concept from the 1940s, when rodents made to gain or lose weight stubbornly returned to baseline once the experiment ended; humans, it emerged, behave the same way. The body, on this model, has a weight it gravitates toward — its — and "obesity results from the initial elevation of the set point to an abnormal level," explains Dr. Lee Kaplan of the Obesity and Metabolism Institute, who consults for more than one . For some patients, the set point appears to malfunction, drifting upward until excess weight begins to compromise health.
Whenever a person tries to push their weight much below that set point, food noise will , and the pattern looks partly physiological: as weight falls, metabolism slows so less food is needed to maintain the new figure, yet the brain simultaneously starts compelling its owner to eat more than the smaller body can burn. That asymmetry is why diets almost always fail , and why food noise is not restricted to people with obesity — anyone whose weight has slipped beneath the body's preferred set point can hear it.
Decades earlier, Dr. Jules Hirsch and his Rockefeller and Columbia colleagues had glimpsed the same dynamic in volunteers, some of normal weight and some not, who lived in hospital on a strict diet until they had shed at least 10 percent of their body mass. They left thinner, but presented the physiological signature of starvation: depressed metabolism, vivid dreams of food, and once no longer subjected to the enforced regime, they binged so badly that the syndrome earned the name "semi-starvation neurosis." It was, Dr. Rudolph Leibel said, "a for ."
Ms. Smith Parker eventually entered a tirzepatide — marketed as Zepbound — at a Yale weight-loss clinic, and the voices simply vanished. When the closed before FDA approval, the food noise returned ; she regained 40 pounds on spaghetti and chocolate cupcakes. Switched onto Wegovy, which had cleared the regulator, she described her head as suddenly, almost startlingly, empty.
Dr. Ania Jastreboff, who runs clinical trials for drug manufacturers and sits on multiple for the pharmaceutical companies that fund them, suspects the GLP-1s are temporarily resetting the set point downward, so patients still feel hunger but the running commentary that once drove their behavior dissolves. Stop the drug, and the original set point returns with the noise; Dr. Leibel likens the effect to aspirin on a fever — it suppresses the symptom without curing the underlying cause.
The unresolved question, Dr. Daniel Drucker calls "the million or billion dollar question": what is being read as "set," and how are the new drugs editing it? Until that mechanism is characterized, obesity will keep being treated as something each patient must out-discipline alone. Oprah Winfrey, who co-wrote a book on the experience with Dr. Jastreboff, describes the silence as the single biggest surprise of her medication; Drucker draws the lesson bluntly: people who never had their brains can afford to be judgmental — but, he insists, they should not be.
Until the new arrived on the market, the term "food noise" lived nowhere on any . Researchers developing Ozempic, Wegovy, Mounjaro and Zepbound measured doses, , and improvements in diabetes, heart disease and , while the incessant chatter inside patients' heads — what to eat, what to resist, when to give in — went entirely unrecorded. Then patients began reporting that the chatter had simply gone quiet, and an unstudied phenomenon walked into the clinic demanding a name.
Lena Smith Parker, 53, spent decades dieting and regaining weight, plagued by an she had long assumed everyone shared. She likens one voice to a relentless auctioneer urging her toward the cake in the kitchen, another to a used-car salesman shaming her vegetables, a third to a flat-out bully, and a fourth to an advance planner staging cupcake runs days ahead. This is the the article names — a churning internal dialogue no clinician used to ask about, because no drug seemed capable of touching it.
To understand why such voices exist, researchers turn to an elusive concept from the 1940s, when rodents made to gain or lose weight stubbornly returned to baseline once the experiment ended; humans, it emerged, behave the same way. The body, on this model, has a weight it gravitates toward — its — and "obesity results from the initial elevation of the set point to an abnormal level," explains Dr. Lee Kaplan of the Obesity and Metabolism Institute, who consults for more than one . For some patients, the set point appears to malfunction, drifting upward until excess weight begins to compromise health.
Whenever a person tries to push their weight much below that set point, food noise will , and the pattern looks partly physiological: as weight falls, metabolism slows so less food is needed to maintain the new figure, yet the brain simultaneously starts compelling its owner to eat more than the smaller body can burn. That asymmetry is why diets almost always fail , and why food noise is not restricted to people with obesity — anyone whose weight has slipped beneath the body's preferred set point can hear it.
Decades earlier, Dr. Jules Hirsch and his Rockefeller and Columbia colleagues had glimpsed the same dynamic in volunteers, some of normal weight and some not, who lived in hospital on a strict diet until they had shed at least 10 percent of their body mass. They left thinner, but presented the physiological signature of starvation: depressed metabolism, vivid dreams of food, and once no longer subjected to the enforced regime, they binged so badly that the syndrome earned the name "semi-starvation neurosis." It was, Dr. Rudolph Leibel said, "a for ."
Ms. Smith Parker eventually entered a tirzepatide — marketed as Zepbound — at a Yale weight-loss clinic, and the voices simply vanished. When the closed before FDA approval, the food noise returned ; she regained 40 pounds on spaghetti and chocolate cupcakes. Switched onto Wegovy, which had cleared the regulator, she described her head as suddenly, almost startlingly, empty.
Dr. Ania Jastreboff, who runs clinical trials for drug manufacturers and sits on multiple for the pharmaceutical companies that fund them, suspects the GLP-1s are temporarily resetting the set point downward, so patients still feel hunger but the running commentary that once drove their behavior dissolves. Stop the drug, and the original set point returns with the noise; Dr. Leibel likens the effect to aspirin on a fever — it suppresses the symptom without curing the underlying cause.
The unresolved question, Dr. Daniel Drucker calls "the million or billion dollar question": what is being read as "set," and how are the new drugs editing it? Until that mechanism is characterized, obesity will keep being treated as something each patient must out-discipline alone. Oprah Winfrey, who co-wrote a book on the experience with Dr. Jastreboff, describes the silence as the single biggest surprise of her medication; Drucker draws the lesson bluntly: people who never had their brains can afford to be judgmental — but, he insists, they should not be.
Questions
Check your understanding
- 01
Why does the article suggest that food noise was unstudied for so long, despite affecting so many patients?
- 02
What does the article imply by comparing the GLP-1 drugs' effect on food noise to aspirin's effect on a fever?
- 03
How does the 1940s research described by Hirsch and his colleagues support the article's broader argument about food noise?
- 04
Assess the claim that obesity is better understood as a brain-behaviour condition than as a failure of personal willpower. Use evidence from the set-point research and the patient accounts to support your answer.
Suggested length: ~100 words
- 05
Argue whether the GLP-1 drugs should be considered a long-term solution to obesity, drawing on what the article tells us about set point, weight regain and the limits of the current evidence.
Suggested length: ~100 words
Questions
Check your understanding
- 01
Why does the article suggest that food noise was unstudied for so long, despite affecting so many patients?
- 02
What does the article imply by comparing the GLP-1 drugs' effect on food noise to aspirin's effect on a fever?
- 03
How does the 1940s research described by Hirsch and his colleagues support the article's broader argument about food noise?
- 04
Assess the claim that obesity is better understood as a brain-behaviour condition than as a failure of personal willpower. Use evidence from the set-point research and the patient accounts to support your answer.
Suggested length: ~100 words
- 05
Argue whether the GLP-1 drugs should be considered a long-term solution to obesity, drawing on what the article tells us about set point, weight regain and the limits of the current evidence.
Suggested length: ~100 words